DA-8159 is a pyrazolopyrimidinone derivative which exhibits potent and selective phosphodiesterase type 5 (PDE5) inhibition. The aim of this study was to investigate the effects of DA-8159 on inducing a penile erection in rabbits with an acute spinal cord injury (ASCI). DA-8159 was given either orally (1, 3, or 10 mg/kg) or intravenously (0.1 or 0.3 mg/kg) to conscious male albino rabbits with a surgical transection of the spinal cord at the L2-L4 lumbar vertebra or ischemic-reperfusion SCI rabbits. Erection was evaluated in a time-course manner by measuring the length of the uncovered penile mucosa. DA-8159 induced a dose-dependent erection in both transection and ischemic-reperfusion ASCI rabbits. The efficacy of DA-8159 was potentiated by an intravenous injection of sodium nitroprusside, a nitric oxide donor. Potentiation of the effect by nitric oxide donor implies that DA-8159 can enhance the erectile activity during sexual arousal. These results suggest that DA-8159 may be useful for treating erectile dysfunction in patients with an SCI.
Introduction
A penile erection is a hemodynamic and neurovascular process in which central (cerebral or spinal) and peripheral factors (smooth muscle and endothelium) are integrated in a complex manner involving the relaxation of the smooth muscle in the corpus cavernosum and its associated arterioles.
1,2 Nitric oxide (NO) played a pivotal role in the endotheliumdependent and neurogenic relaxation of the penile cavernosal smooth muscle, [3] [4] [5] and is released by the parasympathetic nonadrenergic, noncholinergic (NANC) nerves in the trabecular and penile arterial tissues as well as the endothelial cells lining the blood vessels and the lacunar spaces of the corpora cavernosa. 2, [4] [5] [6] The active mechanism of NO on the corpus cavernosum and penile arteries involves the stimulation of cyclic guanosine monophosphate (cGMP) biosynthesis by activating gualylate cyclase. An increased intracellular concentration of cGMP leads to the relaxation of the smooth muscle in the corpus cavernosum and penile arterioles. 4, 7, 8 In penile tissue, cGMP is hydrolyzed by cGMP phosphodiesterase (PDE), and the level of cGMP is regulated by a delicate balance between the rate of synthesis and the rate of hydrolytic breakdown to GMP by the PDE isozymes. 9 Therefore, agents that inhibit the hydrolyzing action of cGMP-specific PDE would be expected to enhance the NO-cGMP signal and thereby enhance the relaxation of the smooth muscle in the corpus cavernosum, which would facilitate the penile erectile responses. 10 The cause of erectile dysfunction (ED) may be broadly classified as organic (from vascular, neurologic, or hormonal causes), psychogenic, or mixed. Neurogenic ED has been termed a form of ED caused by the disruption of the spinal, supraspinal, and/or peripheral nerves involved in sexual function. 11 It has been estimated that 10-19% of ED has a neurogenic origin. 11 Spinal cord injury (SCI) is one of the main causes of neurogenic ED and results in ED in 50% of cases of a lumbar injury. In some men with a spinal injury, only a reflexogenic erection remains.
12 SCI prevents the effective release of NO from the NANC nerves, which prevents the initiation of erection. 13 However, there are currently many therapeutic alternatives to restore erectile function in the SCI patient population. An intracavernosal injection has been shown to be effective in patients with SCI, by direct cavernosal vasorelaxation, which bypasses the neurotransmission signals required to initiate an erection.
14 More recently, sildenafil, an oral treatment agent for ED, has shown some effectiveness in SCI patients. [15] [16] [17] [18] DA-8159 is a selective PDE5 inhibitor developed by Dong-A Pharmaceutical Company as an oral treatment agent for ED. DA-8159 induces a penile erection in a dose-dependent manner both in anesthetized and conscious animals, and induces relaxation of the muscles and increases the endogenous cGMP levels in the rabbit corpus cavernosal smooth muscles. 19, 20 The data obtained from phase 1 clinical study demonstrated that DA-8159 is safe and well tolerated after a single oral dose in healthy Asian or Caucasian males up to 300 or 400 mg without severe adverse events (unpublished data). In this study, the efficacy of DA-8159 in causing an erection in an ischemic-reperfusion model and a spinal cord transection model was examined to assess the effectiveness of DA-8159 for inducing penile erection in rabbits with acute spinal cord injury (ASCI).
Materials and methods

Test materials
DA-8159, a pyrazolopyrimidinone derivative with a molecular weight of 516.66, was synthesized by Dong-A Pharmaceutical Co. (Kyunggi, Korea) with a 499.8% purity as determined by both HPLC and potentiometric titrations in glacial acetic acid. DA-8159 was stable for at least 12 weeks in both the ambient temperature and accelerated conditions (201C, 75% RH). Sodium nitroprusside (SNP) was obtained from the Sigma Chemical Co. (St Louis, MO, USA). DA-8159 was dissolved in a Titrisol s buffer solution (citrate sodium hydroxide buffer, pH 5.0, Merck) for administration.
Animals
The studies were performed in accordance with the institutional standard procedure for animal care and experiments (SOP-ANC) of the Dong-A Pharmaceutical Company and with the 'Guide for the Care and Use of Laboratory Animals' from the National Institutes of Health. New Zealand white rabbits (Kwangsan Laboratory Animals, Korea) weighing an average of 3-4 kg were used in this study. Animals were acclimatized for a week and housed individually. During all experiments, the animals were kept in a standard laboratory conditioned room (temperature 23721C, humidity range 40-70%, 12 h light/dark cycle (lighting: 700 to 1900)) and allowed free access to food and UV-sterilized tap water ad libitum.
Surgical procedure for ischemic-reperfusion SCI model ASCI was induced by the aortic cross-clamping method as described previously. 21, 22 Three rabbits were used in each dosing group. Each animal was anesthetized with an intramuscular injection of xylazine (10 mg/kg) and ketamine (100 mg/kg). An ear vein catheter (22 gauge) was placed for the administration of additional medications and intravenous fluids. Heparin 150 IU/kg was given intravenously and allowed to circulate for 5 min and a 0.9% NaCl solution was infused at a rate of 25 ml/h during the procedure. The abdomen was prepared under sterile conditions and draped. A midline laparotomy was made and the viscera was reflected to the right. The abdominal aorta was then clamped with vascular clamps. One clamp was positioned just below the left renal artery and another was placed at the aortoiliac bifurcation. Each animal underwent 40 min of spinal cord ischemia. The technique of collectively clamping the great vessels produces spinal cord ischemia in the rabbit and after 40 min all control animals were rendered paraplesic, 23, 24 and its reliability and reproducibility is well known. 25 
Surgical procedure for the transection SCI model
Each three-rabbit per group underwent the same anesthetic management, and an ear vein catheter (22 gauge) was placed to administer additional medications and intravenous fluids. Briefly, the lumbodorsal fascia region was exposed and cut in the midline of the spinous processes after a dorsal skin incision of the L2-L4 region. The paraspinous muscle was then separated from the spinous process and the lamina. Bone extending out laterally from the spinous process was removed with a ronguer (laminectomy). It was easier to remove the lamina if the bone was first thinned with a high-speedrotating burr. Once the spinal cord was exposed, spinal cord transection was performed using fine cut scissors or blade between the L2-L3 and L3-L4 region. Ceftazimine was injected intramuscularly with a single dose at 30 mg/kg.
Neurologic examination
At 24 and 48 h after the procedure, the neurologic status was evaluated by Tarlov's scoring system. 26 The criteria were as follows:
T0, spastic paraplegia with no movement of the hind limb;
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Histopathological examination of the spinal cord
The animals were killed at 48 h and their lumbar spinal cords were removed. The tissue samples were fixed in 10% formalin and embedded in paraffin with a routine follow-up procedure. Sections were cut 4 mm thick and stained with hematoxylin and eosin and cresyl violet stains for light microscopic examination. Morphological evaluation of the spinal cords was performed blindly. The histopathological findings were graded as 1-3. 27 Grade 1 indicates the appearance of a normal spinal cord. Grades 2 and 3 denote swollen axons with occasional necrotic neurons and with many necrotic neurons, respectively.
Penile erection test
The animals showing Tarlov's score T0 or T1 were used to perform the penile erection test. Penile erection was evaluated 24 h after the surgical procedure by measuring the length of the exposed penile mucosa with a sliding caliper. DA-8159 was given orally to both the ischemic-reperfusion and the transection SCI model animals at a dose of 1, 3 or 10 mg/kg (n¼3). SNP was dissolved in saline (0.2 mg/kg) and administered into the ear vein of animal with a volume of 1 ml/kg after 60 min of drug administration. For intravenous administration, DA-8159 was given intravenously at the dose of 0.1 or 0.3 mg/kg. SNP was administered 30 min after the drug administration. The length of the exposed penile mucosa was measured every minute for either 90 min (oral) or 60 min (i.v.) after administering the test compound. The mean length of the exposed penile mucosa in each group was calculated. The area under the curve (AUC) was calculated using an integration program (WinNonlin TM Standard, Pharsight Corporation, California, USA). The vehicle was administered either orally or intravenously to the corresponding controls.
Results
Effect of DA-8159 on inducing penile erection in ischemic-reperfusion injury model
Orally administered DA-8159 showed no response for the first 60 min at doses up to 3 mg/kg. However, weak response of exposing the uncovered penile mucosa was observed at 10 mg/kg (Figure 1 ). After 60 min, when the SNP was given intravenously, there was an immediate potentiation of the efficacy of DA-8159 on inducing a penile erection. The dosedependent increase in the length of the uncovered penile mucosa was observed between 1 and 10 mg/ kg of DA-8159, peaking at 10 mg/kg. DA-8159 induced a penile erection with a maximum mean length of 5.7 mm (71.2 mm) at a 10 mg/kg dose ( Figure 1) . When given intravenously, a penile erection was observed at a dose of 0.3 mg/kg with a duration of 30 min after injection of DA-8159. However, no uncovered penile mucosa was observed in the 0.1 mg/kg dose group before the i.v. injection of SNP. The NO donor, SNP, also potentiated the efficacy of DA-8159 on inducing a penile erection in all the dose groups and markedly induced a penile erection with a duration of approximately 10 min at a dose of 0.1 mg/kg, which was not observed before administering SNP (Figure 2 ). The vehicle did not induce a penile erection when given either orally or intravenously.
Effect of DA-8159 on inducing penile erection in transection SCI model Efficacy of DA-8159 in spinal cord injury rabbits BO Ahn et al 10 mg/kg, but there was no change in the length of the uncovered penile mucosa in the 1 mg/kg group. The onset of action occurred at about 35 min in both the 3 and 10 mg/kg dose groups. The intravenous administration of 0.2 mg/kg of the NO donor potentiated the efficacy of DA-8159. At a dose level of 1 mg/kg, this oral dose did not induce a penile erection when given alone. However, the penile erection was significantly increased after administering SNP. In the higher dose groups, the length of the uncovered penile mucosa was also dramatically increased by SNP. The duration of the action time was approximately 30 min with a maximum uncovered penile length of 8.0 mm (71.9 mm) at the dose level of 10 mg/kg of DA-8159 (Figure 3) . The intravenous injection of DA-8159 also induced a penile erection dose-dependently with a duration of approximately 10 or 20 min. After administering SNP, the length of the uncovered penile mucosa and its duration time were potentiated and observed in a dose-dependent manner (Figure 4) . The vehicle did not induce a penile erection given either orally or intravenously.
Area under the curve
The efficacy of DA-8159 is expressed by the AUC using the following formula: time (in minutes) Â the length of the uncovered penile mucosa (in mm). The effect of the SNP injection alone was subtracted. In the ischemic-reperfusion model, an oral dose of 1 Table 1 ).
Histopathological examination of spinal cord
In animals with a Tarlov's score T1 and T0, which were used in this study, there was markedly increased neuronal degeneration including shrunken neuron and Nissl substance disappearance, and neuronal necrosis in the lumber spinal cord (L6). These changes were most pronounced within the ventral horn motor neurons from each spinal cord section. The grades of the lesions were 2 or 3 in all rabbits ( Figure 5 ).
Discussion
In this study, DA-8159 was demonstrated to induce a penile erection in rabbits with ASCIs such as ischemic-reperfusion and spinal cord transection models. In addition, this study showed that this erectile response was markedly potentiated by SNP, an NO donor.
ED is common among SCI patients 28 and there are many therapeutic alternatives to restore erectile function in these patients. Mechanical therapies, such as a penile prosthesis or vacuum/constriction tumescence, have been utilized. However, because of the potential problems associated with the vacuum erectile device and prosthesis, research in non-invasive pharmacological manipulation of the erectile function continues. The oral ingestion of a systemic alpha-adrenergic antagonist, such as yohimbine, local vasoactive substances, or a topical nitroglycerine paste have been tried but with limited success in SCI patients. 13, [28] [29] [30] Recently, sildenafil was found to improve the erectile function in patients with SCI. [15] [16] [17] [18] NO released from the NANC neurons is not the only mechanism involved in an erection. 31 The endothelial cells also release an endothelium-derived relaxing factor, or NO, which diffuses to the adjacent smooth muscle cells and causes them to relax. 32 This indicates that the cGMP accumulation in cavernosal smooth muscle depends not only on a prior endogenous NANC stimulus but also on the parasympathetic drive acting through NO. Therefore, the relaxing action of a PDE5 inhibitor is at least partially mediated by the endothelium. This proposal describes why sildenafil treatment improves the erectile function in patients with ED secondary to a traumatic SCI, with no difference in the patients who did and did not have a residual erectile function. 33 Numerous and extensive studies have been performed to clarify anatomic, physiologic, and biochemical aspects of traumatic SCI. 34 Oxygen radical-mediated lipid peroxidation has been suggested to be an important factor in post-traumatic neuronal degeneration. Lipid peroxidation can involve the undamaged neuronal tissue circumferentially, resulting in collapse of the microcirculation and lead to irreversible damage to the myelin and axons. Similar pathophysiologic changes also occur in ischemic spinal injury. 35 It is also well known that post-ischemic neurological dysfunction including paraparesia and paraplegia was easily induced by ischemia such as aortic cross-clamping, because of the unique segmental arterial blood supply to the Efficacy of DA-8159 in spinal cord injury rabbits BO Ahn et al spinal cord from the infrarenal artery in this animal. 36 The results, as shown in Figure 5 , indicate that spinal cords of the ischemic-reperfusion injured rabbits have neuronal degeneration and a Nissl substance disappearance, which means this model can be applicable to the neurogenic ED model. In addition, the neurological status of all the animals exhibits spastic paraplegia with or without the hind limb motor function as shown by the Tarlov's score. Therefore, a rabbit model with spinal cord ischemia was used to assess the efficacy of DA-8159 on a penile erection in spinal cord injured rabbits.
A simple surgical transection of the spinal cord fails to model complete human SCI, since such a condition is rarely encountered in humans, but offers the distinct advantage of consistent reproducibility. In rabbits, the penis receives innervation from the pelvic parasympathetic nerves (sacral) and the sympathetic hypogastric nerves (thoracolumbar). On the other hand, it is known that a penile erection is an involuntary or a reflex phenomenon elicited by a variety of reflexogenic and psychogenic stimuli and by two distinct central mechanisms (ie, supraspinal and spinal center). A psychogenic erection is initiated by the supraspinal centers and this reflex pathway is carried by both the thoracolumbar (sympathetic) and sacral (parasympathetic) autonomic outflow. A reflexogenic penile erection is caused by the exteroceptive stimulation of the genital regions and is mediated by the sacral reflex pathway, which consists of afferent (pudendal nerve) and efferent (sacral parasympathetic nerve) nerves. 37, 38 Therefore, it is postulated that the rabbit models used in these experiments have some residual erectile potentials that are mediated by the sympathetic hypogastric nerves and the sacral reflex pathway because the L2-L4 vertebra was transected. These conditions are more relevant to human ED with SCI since the population with SCI has some potential for a reflexogenic erection. 12 Figure 1 and 2 demonstrate the efficacy of DA-8159 in the ischemic-reperfusion model. Before injecting the SNP, the minimum effective doses were found to be 10 mg/kg orally and 0.3 mg/kg intravenously. It is believed that these high doses were required because of the lack of sexual stimulation or exogenous NO in the rabbit model. However, the length of the uncovered mucosa and the duration of penile erection were immediately potentiated by SNP and showed a dose-dependency. The minimum effective doses were 1 mg/kg (oral) and 0.1 mg/kg (i.v.). The erectogenic potential of DA-8159 in the spinal cord transection model is shown in Figures 3 and 4 . Similar to the results observed in the ischemic-reperfusion model, DA-8159 induced a penile erection at 3 and 10 mg/kg orally, and 0.1 and 0.3 mg/kg intravenously. Its efficacy was also markedly potentiated by SNP. As is well known, a penile erection is mediated by NO released on nerve terminals. However, under these experimental conditions, SNP replaced the naturally released NO and enhanced the efficacy of DA-8159. This dependency of efficacy on NO suggests that DA-8159 would result in enhanced penile activity during sexual arousal.
Conclusion
This study used the ischemic-reperfusion injury model and the spinal cord transection model to assess the efficacy of DA-8159 on inducing a penile erection in spinal cord injured rabbits. DA-8159, when given either orally or intravenously, induced a dose-dependent erection in both the transection and ischemic-reperfusion acute spinal cord injured rabbits. Its efficacy was potentiated by an intravenous SNP, an NO donor. These findings suggest that the efficacy of DA-8159 would enhance erectogenic potential during sexual arousal, and DA-8159 may be a useful treatment agent for erectile dysfunction in patients with an SCI.
